Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma

Starting soon

Conditions studied: HCC, Adjuvant Therapy, Recurrence, Immune Checkpoint Inhibitor

In brief

Early hepatocellular carcinoma (HCC) recurrence (driven by residual tumors) and late recurrence (driven by de novo tumors) exhibit distinct biological behaviors, suggesting differential therapeutic vulnerabilities. The beneficiaries of adjuvant PD-1 inhibitors (aPD-1) and their efficacy across these temporally divergent recurrence patterns remains unestablished.

Key facts

Study ID

NCT07379489

Run by

Tongji Hospital

People needed

300

Starts

2026-01-31

Expected to finish

2031-12-31

Last updated by the study team

2026-01-30

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Aged between 18 and 75;
• achieved complete tumor resection;
• histological verification of HCC;
• liver function classified as Child-Pugh grade A or B;
• No other serious systemic disease or organ dysfunction.

You may not qualify if…

• history of other malignancies or recurrent HCC;
• extrahepatic metastasis;
• prior treatments for HCC;
• ongoing severe postoperative complications;
• mixed or other types of liver cancer;
• received other adjuvant therapy.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.